| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,969 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
110,593 |
276,438 |
434,458 |
898,780 |
| Total Sell Value |
$6,689,254 |
$18,972,868 |
$24,231,754 |
$44,996,315 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
9 |
21 |
39 |
85 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wolff Andrew A |
SVP & CMO |
• – – |
2015-03-11 |
4 |
OE |
$6.30 |
$137,813 |
D/D |
21,875 |
43,036 |
|
- |
|
| Malik Fady Ibraham |
SVP Research & Development |
• – – |
2014-12-30 |
4 |
S |
$6.73 |
$145,676 |
D/D |
(21,630) |
3,361 |
|
- |
|
| Gage L Patrick |
Director |
– • – |
2014-05-09 |
4 |
B |
$4.10 |
$3,485 |
I/I |
850 |
850 |
2.1 |
- |
|
| Gage L Patrick |
Director |
– • – |
2014-05-09 |
4 |
B |
$4.09 |
$40,892 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Dart Kenneth Bryan |
10% Owner |
– – • |
2014-02-25 |
4 |
B |
$8.00 |
$4,000,000 |
D/D |
500,000 |
2,883,845 |
2.45 |
- |
|
| Blum Robert I |
President & CEO |
• • – |
2013-12-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
18,000 |
3,276 |
|
- |
|
| Barbari Sharon Surrey |
EVP, Finance & CFO |
• – – |
2013-09-03 |
4 |
D |
$7.65 |
$47,904 |
D/D |
(6,262) |
24,778 |
|
- |
|
| Barbari Sharon Surrey |
EVP, Finance & CFO |
• – – |
2013-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,666 |
31,040 |
|
- |
|
| Malik Fady Ibraham |
SVP Research & Early Dev |
• – – |
2013-09-03 |
4 |
D |
$7.65 |
$41,914 |
D/D |
(5,479) |
24,367 |
|
- |
|
| Malik Fady Ibraham |
SVP Research & Early Dev |
• – – |
2013-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,583 |
29,846 |
|
- |
|
| Wolff Andrew A |
SVP Clinical R&D, CMO |
• – – |
2013-09-03 |
4 |
D |
$7.65 |
$41,914 |
D/D |
(5,479) |
20,637 |
|
- |
|
| Wolff Andrew A |
SVP Clinical R&D, CMO |
• – – |
2013-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,583 |
26,116 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2013-09-03 |
4 |
D |
$7.65 |
$29,934 |
D/D |
(3,913) |
16,266 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2013-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,416 |
20,179 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2013-09-03 |
4 |
D |
$7.65 |
$83,836 |
D/D |
(10,959) |
21,276 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2013-09-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,166 |
32,235 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2012-12-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
110,895 |
18,416 |
|
- |
|
| Dow Stephen M |
Director |
– • – |
2012-11-14 |
4 |
S |
$0.61 |
$1,063,374 |
I/I |
(1,742,950) |
1,421,052 |
|
- |
|
| Malik Fady Ibraham |
SVP Research & Early Dev |
• – – |
2012-09-04 |
4 |
D |
$0.76 |
$24,353 |
D/D |
(32,052) |
89,080 |
|
- |
|
| Malik Fady Ibraham |
SVP Research & Early Dev |
• – – |
2012-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,500 |
121,132 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2012-09-04 |
4 |
D |
$0.76 |
$48,707 |
D/D |
(64,105) |
129,311 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2012-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
175,000 |
193,416 |
|
- |
|
| Wolff Andrew A |
SVP Clinical R&D, CMO |
• – – |
2012-09-04 |
4 |
D |
$0.76 |
$24,353 |
D/D |
(32,052) |
66,698 |
|
- |
|
| Wolff Andrew A |
SVP Clinical R&D, CMO |
• – – |
2012-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
87,500 |
98,750 |
|
- |
|
| Cragg David |
SVP Human Resources |
• – – |
2012-09-04 |
4 |
D |
$0.76 |
$17,395 |
D/D |
(22,894) |
56,081 |
|
- |
|
1112 Records found
|
|
Page 30 of 45 |
|
|
1.22 (2.31%) 
